Steroid Plus Sirolimus vs. Steroid Alone for New Autoimmune Anemia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests whether adding a medication called sirolimus to steroid treatment works better than steroids alone for newly diagnosed autoimmune hemolytic anemia (a condition where your body attacks its own red blood cells). You'll be randomly assigned to one treatment group, and researchers will track how well each approach helps your body recover.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have newly diagnosed autoimmune hemolytic anemia and need immune-suppressing medication (you may have taken steroids for up to 2 weeks before joining)
- Your blood test shows positive Coombs result (a test that detects antibodies attacking red blood cells)
- Your hemoglobin level is 100 g/L or lower (indicating active anemia)
- Your liver and kidney function tests are near normal (ALT less than 3× normal, creatinine less than 2× normal)
- You have not taken other immune-suppressing drugs or steroids for more than 2 weeks before enrollment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new therapy called META 10-19 for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not responded to or has come back after standard treatments. It aims to see if this treatment can help control the disease.
This trial studies sirolimus in adults with “warm” autoimmune hemolytic anemia (or Evans syndrome) when steroids have not worked or the anemia has returned. It may help control the immune attack on red blood cells, but there are specific safety checks for liver health and infections.
This trial tests if sirolimus (an immune-suppressing drug) works better than current treatments for aplastic anemia patients who did not improve or had side effects from cyclosporin. It aims to find a new option to help your body make more blood cells.
This trial tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) that hasn't improved after at least three prior treatments. It aims to see if the therapy can help control the disease and improve anemia symptoms.
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
This Phase 3 study tests a second-line treatment for adults with warm autoimmune hemolytic anemia whose disease is not controlled with steroids, who cannot tolerate steroids, or who decline standard treatment. It aims to improve anemia and reduce ongoing red blood cell destruction caused by the immune system.
Hear when a new Autoimmune Hemolytic Anemia (AIHA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.